{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:40:00Z","timestamp":1793522400918,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"8131","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression\n                    <jats:sup>1<\/jats:sup>\n                    . In hormone receptor-positive (HR\n                    <jats:sup>+<\/jats:sup>\n                    ) breast cancer, CDK4\/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens\n                    <jats:sup>2<\/jats:sup>\n                    . How pharmacologically activated Rb remodels chromatin and influences transcription beyond cell cycle arrest remains poorly understood. Here we show that CDK4\/6 inhibition induces redistribution of hypophosphorylated Rb to promoters and enhancers. Although Rb predictably binds to cell cycle gene promoters to repress transcription, at other sites, it unexpectedly promotes expression of oestrogen-responsive genes by integrating into oestrogen receptor (ER)-rich transcriptional hubs. CDK4\/6 inhibition enhances ER target gene expression in breast cancer cells, patient-derived xenografts and clinical HR\n                    <jats:sup>+<\/jats:sup>\n                    breast cancer samples in an Rb-dependent manner. This reprogramming is mediated in part by KDM5A, whose interaction with Rb contributes to gene regulation at these loci. Critically, components of this Rb-driven ER transcriptional program are pro-proliferative. In endocrine-sensitive tumours, this effect\u00a0can be neutralized with anti-oestrogen therapy, explaining therapeutic synergy. In endocrine-resistant settings such as\n                    <jats:italic>ESR1<\/jats:italic>\n                    -mutant breast cancer, the program persists, limiting the\u00a0therapeutic efficacy\u00a0of\u00a0CDK4\/6 inhibition. These findings reframe Rb as a dual-function transcriptional regulator that, although enforcing cell cycle arrest, can also activate programs that counteract its tumour suppressor function.\n                  <\/jats:p>","DOI":"10.1038\/s41586-026-10886-w","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:02:11Z","timestamp":1786546931000},"page":"517-524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rb-driven transcription limits its tumour-suppressive effects in breast cancer"],"prefix":"10.1038","volume":"657","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5145-5334","authenticated-orcid":false,"given":"April C.","family":"Watt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6653-1723","authenticated-orcid":false,"given":"Catherine","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia R.","family":"Dixon-Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krutika","family":"Ambani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Coulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1115-5449","authenticated-orcid":false,"given":"Michael","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-3724","authenticated-orcid":false,"given":"Keefe T.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-5283","authenticated-orcid":false,"given":"Brendan E.","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Ramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christabella A.","family":"Mahendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-2927","authenticated-orcid":false,"given":"Nichelle","family":"Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2344-1246","authenticated-orcid":false,"given":"Jesus","family":"Garcia-Sannicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1168-8521","authenticated-orcid":false,"given":"Olivia","family":"Voulgaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Nunag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Seng","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-5029","authenticated-orcid":false,"given":"Mark A.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-8838","authenticated-orcid":false,"given":"Elgene","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Arnedos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4532-8053","authenticated-orcid":false,"given":"Sarat","family":"Chandarlapaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-8357","authenticated-orcid":false,"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-9084","authenticated-orcid":false,"given":"Shom","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"10886_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc2399","volume":"8","author":"DL Burkhart","year":"2008","unstructured":"Burkhart, D. L. & Sage, J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 8, 671\u2013682 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"10886_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel, S., Bergholz, J. S. & Zhao, J. J. Targeting CDK4 and CDK6 in cancer. Nat. Rev. Cancer 22, 356\u2013372 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"10886_CR3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/375812a0","volume":"375","author":"SJ Weintraub","year":"1995","unstructured":"Weintraub, S. J. et al. Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375, 812\u2013815 (1995).","journal-title":"Nature"},{"key":"10886_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/358259a0","volume":"358","author":"SJ Weintraub","year":"1992","unstructured":"Weintraub, S. J., Prater, C. A. & Dean, D. C. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358, 259\u2013261 (1992).","journal-title":"Nature"},{"key":"10886_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1101\/gad.6.2.177","volume":"6","author":"SW Hiebert","year":"1992","unstructured":"Hiebert, S. W., Chellappan, S. P., Horowitz, J. M. & Nevins, J. R. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. 6, 177\u2013185 (1992).","journal-title":"Genes Dev."},{"key":"10886_CR6","doi-asserted-by":"publisher","first-page":"11544","DOI":"10.1073\/pnas.92.25.11544","volume":"92","author":"WR Sellers","year":"1995","unstructured":"Sellers, W. R., Rodgers, J. W. & Kaelin, W. G. Jr. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc. Natl Acad. Sci. USA 92, 11544\u201311548 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10886_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0092-8674(00)81519-6","volume":"98","author":"JW Harbour","year":"1999","unstructured":"Harbour, J. W., Luo, R. X., Dei Santi, A., Postigo, A. A. & Dean, D. C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98, 859\u2013869 (1999).","journal-title":"Cell"},{"key":"10886_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.tcb.2023.07.012","volume":"34","author":"I Sanidas","year":"2024","unstructured":"Sanidas, I., Lawrence, M. S. & Dyson, N. J. Patterns in the tapestry of chromatin-bound RB. Trends Cell Biol. 34, 288\u2013298 (2024).","journal-title":"Trends Cell Biol."},{"key":"10886_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring, L. M. et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395, 817\u2013827 (2020).","journal-title":"Lancet"},{"key":"10886_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","volume":"14","author":"C Dietrich","year":"2024","unstructured":"Dietrich, C. et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 14, 446\u2013467 (2024).","journal-title":"Cancer Discov."},{"key":"10886_CR11","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/374562a0","volume":"374","author":"P Singh","year":"1995","unstructured":"Singh, P., Coe, J. & Hong, W. A role for retinoblastoma protein in potentiating transcriptional activation by the glucocorticoid receptor. Nature 374, 562\u2013565 (1995).","journal-title":"Nature"},{"key":"10886_CR12","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1126\/science.8493578","volume":"260","author":"CY Wang","year":"1993","unstructured":"Wang, C. Y., Petryniak, B., Thompson, C. B., Kaelin, W. G. & Leiden, J. M. Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. Science 260, 1330\u20131335 (1993).","journal-title":"Science"},{"key":"10886_CR13","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/emboj\/17.8.2342","volume":"17","author":"MA Nead","year":"1998","unstructured":"Nead, M. A., Baglia, L. A., Antinore, M. J., Ludlow, J. W. & McCance, D. J. Rb binds c-Jun and activates transcription. EMBO J. 17, 2342\u20132352 (1998).","journal-title":"EMBO J."},{"key":"10886_CR14","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1038\/sj.onc.1203118","volume":"18","author":"Y Konishi","year":"1999","unstructured":"Konishi, Y. et al. GOOSECOID inhibits erythrocyte differentiation by competing with Rb for PU.1 binding in murine cells. Oncogene 18, 6795\u20136805 (1999).","journal-title":"Oncogene"},{"key":"10886_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/35087620","volume":"412","author":"SJ Nielsen","year":"2001","unstructured":"Nielsen, S. J. et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 412, 561\u2013565 (2001).","journal-title":"Nature"},{"key":"10886_CR16","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1016\/j.molcel.2022.07.014","volume":"82","author":"I Sanidas","year":"2022","unstructured":"Sanidas, I. et al. Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression. Mol. Cell 82, 3333\u20133349.e9 (2022).","journal-title":"Mol. Cell"},{"key":"10886_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq6858","volume":"10","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. The G1-S transition is promoted by Rb degradation via the E3 ligase UBR5. Sci. Adv. 10, eadq6858 (2024).","journal-title":"Sci. Adv."},{"key":"10886_CR18","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.21856","volume":"6","author":"PJ Skene","year":"2017","unstructured":"Skene, P. J. & Henikoff, S. An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. eLife 6, e21856 (2017).","journal-title":"eLife"},{"key":"10886_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0092-8674(00)80940-X","volume":"92","author":"RX Luo","year":"1998","unstructured":"Luo, R. X., Postigo, A. A. & Dean, D. C. Rb interacts with histone deacetylase to repress transcription. Cell 92, 463\u2013473 (1998).","journal-title":"Cell"},{"key":"10886_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/35404","volume":"391","author":"A Brehm","year":"1998","unstructured":"Brehm, A. et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391, 597\u2013601 (1998).","journal-title":"Nature"},{"key":"10886_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61797-9","volume":"16","author":"P Hunold","year":"2025","unstructured":"Hunold, P. et al. DynaTag for efficient mapping of transcription factors in low-input samples and at single-cell resolution. Nat. Commun. 16, 6585 (2025).","journal-title":"Nat. Commun."},{"key":"10886_CR22","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1038\/nprot.2013.150","volume":"8","author":"S Wang","year":"2013","unstructured":"Wang, S. et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA. Nat. Protoc. 8, 2502\u20132515 (2013).","journal-title":"Nat. Protoc."},{"key":"10886_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s43018-020-00135-y","volume":"2","author":"AC Watt","year":"2021","unstructured":"Watt, A. C. et al. CDK4\/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat. Cancer 2, 34\u201348 (2021).","journal-title":"Nat. Cancer"},{"key":"10886_CR24","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1093\/nar\/gku463","volume":"42","author":"RP Welch","year":"2014","unstructured":"Welch, R. P. et al. ChIP-Enrich: gene set enrichment testing for ChIP-seq data. Nucleic Acids Res. 42, e105 (2014).","journal-title":"Nucleic Acids Res."},{"key":"10886_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10886_CR26","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"10886_CR27","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/annonc\/mdy202","volume":"29","author":"M Arnedos","year":"2018","unstructured":"Arnedos, M. et al. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. Ann. Oncol. 29, 1755\u20131762 (2018).","journal-title":"Ann. Oncol."},{"key":"10886_CR28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.CCR-14-2258","volume":"21","author":"A DeMichele","year":"2015","unstructured":"DeMichele, A. et al. CDK 4\/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin. Cancer Res. 21, 995\u20131001 (2015).","journal-title":"Clin. Cancer Res."},{"key":"10886_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.cell.2019.06.026","volume":"178","author":"J Guan","year":"2019","unstructured":"Guan, J. et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell 178, 949\u2013963.e18 (2019).","journal-title":"Cell"},{"key":"10886_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39613-z","volume":"14","author":"EF Schuster","year":"2023","unstructured":"Schuster, E. F. et al. Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2\u2212 postmenopausal breast cancers. Nat. Commun. 14, 4017 (2023).","journal-title":"Nat. Commun."},{"key":"10886_CR31","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu, M. T. et al. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 76, 2301\u20132313 (2016).","journal-title":"Cancer Res."},{"key":"10886_CR32","doi-asserted-by":"publisher","unstructured":"Li, Q. et al. INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1726 (2021).","DOI":"10.1158\/2159-8290.CD-20-1726"},{"key":"10886_CR33","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41586-021-03474-7","volume":"592","author":"AC Chaikovsky","year":"2021","unstructured":"Chaikovsky, A. C. et al. The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D. Nature 592, 794\u2013798 (2021).","journal-title":"Nature"},{"key":"10886_CR34","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1158\/1535-7163.MCT-17-0290","volume":"17","author":"N O\u2019Brien","year":"2018","unstructured":"O\u2019Brien, N. et al. Preclinical activity of abemaciclib alone or in combination with antimitotic and targeted therapies in breast cancer. Mol. Cancer Ther. 17, 897\u2013907 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"10886_CR35","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439\u20131445 (2013).","journal-title":"Nat. Genet."},{"key":"10886_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00617-7","volume":"10","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary, N. et al. CDK4\/6i-treated HR+\/HER2\u2212 breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ Breast Cancer 10, 15 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"10886_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502929","author":"FC Bidard","year":"2025","unstructured":"Bidard, F. C. et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2502929 (2025).","journal-title":"N. Engl. J. Med."},{"key":"10886_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.molcel.2005.05.012","volume":"18","author":"EV Benevolenskaya","year":"2005","unstructured":"Benevolenskaya, E. V., Murray, H. L., Branton, P., Young, R. A. & Kaelin, W. G. Jr. Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol. Cell 18, 623\u2013635 (2005).","journal-title":"Mol. Cell"},{"key":"10886_CR39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.cell.2007.02.013","volume":"128","author":"RJ Klose","year":"2007","unstructured":"Klose, R. J. et al. The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 128, 889\u2013900 (2007).","journal-title":"Cell"},{"key":"10886_CR40","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1101\/gad.328336.119","volume":"33","author":"MG Oser","year":"2019","unstructured":"Oser, M. G. et al. The KDM5A\/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes Dev. 33, 1718\u20131738 (2019).","journal-title":"Genes Dev."},{"key":"10886_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-023-05780-8","volume":"615","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. H3K4me3 regulates RNA polymerase II promoter-proximal pause-release. Nature 615, 339\u2013348 (2023).","journal-title":"Nature"},{"key":"10886_CR42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinformatics 20, 587\u2013596 (2022).","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10886_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25422-9","volume":"12","author":"CL Alves","year":"2021","unstructured":"Alves, C. L. et al. Co-targeting CDK4\/6 and AKT with endocrine therapy prevents progression in CDK4\/6 inhibitor and endocrine therapy-resistant breast cancer. Nat. Commun. 12, 5112 (2021).","journal-title":"Nat. Commun."},{"key":"10886_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","volume":"29","author":"S Goel","year":"2016","unstructured":"Goel, S. et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors. Cancer Cell 29, 255\u2013269 (2016).","journal-title":"Cancer Cell"},{"key":"10886_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"10886_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01670-2","volume":"22","author":"Y Ma","year":"2024","unstructured":"Ma, Y. et al. Inhibition of p21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity. Cell Commun. Signal. 22, 287 (2024).","journal-title":"Cell Commun. Signal."},{"key":"10886_CR47","doi-asserted-by":"publisher","first-page":"e0185056","DOI":"10.1371\/journal.pone.0185056","volume":"12","author":"B Bushnell","year":"2017","unstructured":"Bushnell, B., Rood, J. & Singer, E. BBMerge\u2014accurate paired shotgun read merging via overlap. PLoS ONE 12, e0185056 (2017).","journal-title":"PLoS ONE"},{"key":"10886_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"10886_CR49","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12859-018-2353-5","volume":"19","author":"RJC Kluin","year":"2018","unstructured":"Kluin, R. J. C. et al. XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data. BMC Bioinformatics 19, 366 (2018).","journal-title":"BMC Bioinformatics"},{"key":"10886_CR50","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"10886_CR51","doi-asserted-by":"publisher","first-page":"D916","DOI":"10.1093\/nar\/gkaa1087","volume":"49","author":"A Frankish","year":"2021","unstructured":"Frankish, A. et al. Gencode 2021. Nucleic Acids Res. 49, D916\u2013D923 (2021).","journal-title":"Nucleic Acids Res."},{"key":"10886_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"10886_CR53","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"10886_CR54","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.12688\/f1000research.8967.1","volume":"5","author":"B Klaus","year":"2016","unstructured":"Klaus, B. & Reisenauer, S. An end to end workflow for differential gene expression using Affymetrix microarrays. F1000Res. 5, 1384 (2016).","journal-title":"F1000Res."},{"key":"10886_CR55","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma Powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"10886_CR56","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"10886_CR57","unstructured":"Picard Toolkit (Broad Institute, 2019)."},{"key":"10886_CR58","doi-asserted-by":"publisher","unstructured":"Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience https:\/\/doi.org\/10.1093\/gigascience\/giab008 (2021).","DOI":"10.1093\/gigascience\/giab008"},{"key":"10886_CR59","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"10886_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"10886_CR61","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature10730","volume":"481","author":"CS Ross-Innes","year":"2012","unstructured":"Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389\u2013393 (2012).","journal-title":"Nature"},{"key":"10886_CR62","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/bioinformatics\/btv145","volume":"31","author":"G Yu","year":"2015","unstructured":"Yu, G., Wang, L. G. & He, Q. Y. ChIPseeker: an R\/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics 31, 2382\u20132383 (2015).","journal-title":"Bioinformatics"},{"key":"10886_CR63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"10886_CR64","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"},{"key":"10886_CR65","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.molcel.2019.01.006","volume":"73","author":"J Petrovic","year":"2019","unstructured":"Petrovic, J. et al. Oncogenic Notch promotes long-range regulatory interactions within hyperconnected 3D cliques. Mol. Cell 73, 1174\u20131190.e12 (2019).","journal-title":"Mol. Cell"},{"key":"10886_CR66","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."},{"key":"10886_CR67","doi-asserted-by":"publisher","unstructured":"Ahn, A. Goel-laboratory\/Rb-transcription-limits-tumour-suppression: code associated with \u2018Rb-driven transcription limits its tumour suppressive effects in breast cancer\u2019\u2014v1.0.0\u2019. Zenodo https:\/\/doi.org\/10.5281\/zenodo.20789312 (2026).","DOI":"10.5281\/zenodo.20789312"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10886-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10886-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10886-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:38:48Z","timestamp":1789018728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10886-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":67,"journal-issue":{"issue":"8131","published-print":{"date-parts":[[2026,9,10]]}},"alternative-id":["10886"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10886-w","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.G. has received research funding from Eli Lilly, G1 Therapeutic and Incyclix Bio; and served as a paid advisor for Eli Lilly, Pfizer, Novartis, BeiGene, Belharra Therapeutics and Halda Therapeutics. J.R.D.-D. has received support of travel and accommodation expenses from Pierre Fabre, MSD and Novartis; and received personal honoraria from Gilead Life Sciences. M.A. has received research funding from AstraZeneca and Roche-Genentech; served as a paid advisor for Eli Lilly, Novartis, AstraZeneca, Gilead, Daiichi-Sankyo, Menarini and Pfizer; and received travel grants from Novartis, AstraZeneca, Eli-Lilly and Daiichi-Sankyo. S.C. has received institutional grant funding from Daiichi-Sankyo and AstraZeneca; holds share options in Totus Medicines; and received honoraria as a consultant to Daiichi-Sankyo, AstraZeneca, Lilly, Casdin Capital, Merck, Nuvalent and Pathos AI. F.A. has received research grants or advisory board funds (paid to institutions) from AstraZeneca, Daiichi-Sankyo, Lilly, Novartis, BMS, Pfizer, Relay Therapeutics and Roche; and received honoraria from Relay Therapeutics, Lilly and AstraZeneca.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}